Retatrutide: What the Research Actually Shows
Last updated: October 3, 2026
Retatrutide (LY3437943) produced a mean −25.0% body weight change on 12 mg at 80 weeks in Eli Lilly's Phase 3 TRIUMPH-1 obesity trial, per the peer-reviewed NEJM paper (PMID 42814954, intention-to-treat estimand). A higher 28.3% figure is company-reported (Lilly's efficacy estimand) and does not appear in the peer-reviewed paper's abstract; source: Lilly's topline release (May 21, 2026). The earlier Phase 2 trial (NEJM 2023) reported 24.2% at 48 weeks. It works by simultaneously activating three metabolic receptors: GLP-1, GIP, and glucagon.
Code HIGHPEPTIDES takes 15% off at checkout: $68
Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.
(12mg, 80 weeks, TRIUMPH-1, ITT)
(TRIUMPH-1)
(GIP + GLP-1 + Glucagon)
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
Phase 3 TRIUMPH-1 has reported — −25.0% mean weight change on 12 mg
In Eli Lilly's Phase 3 TRIUMPH-1 obesity trial (80 weeks), the peer-reviewed NEJM paper (PMID 42814954) reports a mean −25.0% body weight change on 12 mg under intention-to-treat, versus −3.9% with placebo. The original Phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315) reported 24.2% on 12 mg at 48 weeks. Retatrutide remains investigational and is not yet FDA-approved.
Mechanism of Action
A Triple Receptor Agonist
Retatrutide (LY3437943) simultaneously activates three metabolic receptors, a combination no approved drug achieves. Here is what each target is thought to do.
GLP-1 Receptor
Thought to reduce appetite, slow gastric emptying, and enhance insulin secretion in response to meals. This is the same target as semaglutide (Ozempic/Wegovy).
GIP Receptor
Thought to support insulin secretion and fat metabolism. This is the same second target used by tirzepatide (Mounjaro/Zepbound).
Glucagon Receptor
The third target. Glucagon-receptor activation is thought to raise energy expenditure and liver fat metabolism. This is a proposed mechanism, not a result measured in the retatrutide trials cited here.
Phase 2 Trial Data
Weight Loss by Dose
Average percent body weight lost across all dose groups, measured at 24 and 48 weeks. Bars animate when you scroll to this section.
48-Week Outcomes
Who Actually Loses Weight?
Percentage of participants achieving meaningful weight loss thresholds at 48 weeks. The higher the dose, the more consistent the results.
Competitive Landscape
How Does It Compare?
Retatrutide vs the two leading approved GLP-1 medications. Figures are each drug's highest-dose mean change from its own placebo-controlled trial (treatment-regimen / intention-to-treat estimand) — cross-trial numbers, see the note below.
(GIP + GLP-1 + GCG)
(12 mg, 80 weeks, TRIUMPH-1, ITT; PMID 42814954)
(GIP + GLP-1)
(15 mg, 72 weeks, SURMOUNT-1; Jastreboff et al., NEJM 2022, PMID 35658024)
(GLP-1 only)
(2.4 mg, 68 weeks, STEP 1; Wilding et al., NEJM 2021, PMID 33567185)
Safety Profile
Side Effects Breakdown
What the published trial abstracts report about safety. Per-event rates by dose are in the full papers and are not reproduced here.
Titration Matters
Starting at 2mg and slowly titrating up to higher doses partially mitigated GI side effects compared to starting directly at 4mg in the phase 2 trial (PMID 37366315).
What the Abstracts Don't Report
Neither trial abstract gives per-event adverse-event percentages or a discontinuation rate due to adverse events, so this page does not state them. See the full NEJM papers for those figures.
Dose and Tolerability
Because GI events were dose-related in phase 2, higher doses carried more of them. Long-term safety beyond the trial periods has not been established.
Study Metadata
Trial Details
The trial details below are from the Phase 2 NEJM publication; other figures on this page are cited where they appear. Full citation below.
Phase 2 Randomized Controlled Trial
Retatrutide (LY3437943) for Obesity — Full Study Record
Phase 3: TRIUMPH Program Results
Phase 3 TRIUMPH: Results & What's Next
Eli Lilly's Phase 3 TRIUMPH-1 obesity trial has now been published in NEJM. Here is what the paper reports.
Phase 3 Weight Loss Data: Reported
Eli Lilly's Phase 3 TRIUMPH-1 obesity trial (80 weeks, 2339 participants randomized) reported a mean body weight change of −25.0% on 12 mg, −23.7% on 9 mg and −17.6% on 4 mg, versus −3.9% with placebo, under the intention-to-treat estimand (NEJM, PMID 42814954). Lilly's topline release gave a higher, company-reported 28.3% for 12 mg under Lilly's efficacy estimand; that figure does not appear in the peer-reviewed paper's abstract. For context, the Phase 2 trial reported 24.2% on 12 mg at 48 weeks (Jastreboff et al., NEJM 2023, PMID 37366315). The TRIUMPH-1 paper reports WOMAC knee-pain score changes of up to −4.1 points (ITT; −2.5 with placebo) in participants with knee osteoarthritis, and apnea-hypopnea index changes of up to −34.3 events/hour (9 mg, ITT; vs −9.6 with placebo) in participants with obstructive sleep apnea.
What the TRIUMPH Program Covers
TRIUMPH-1 enrolled adults with obesity without diabetes, with prespecified subgroups of 574 participants with knee osteoarthritis and 243 with obstructive sleep apnea (PMID 42814954). Results from Lilly's other TRIUMPH trials are not covered on this page.
Retatrutide remains investigational and is not FDA-approved.
Self-Assessment
Who Researches Retatrutide?
This Research Is Commonly Explored By People Who...
- Are interested in the next generation of multi-receptor agonists (GLP-1/GIP/glucagon triple agonist)
- Want to understand Phase 2 data showing up to 24% weight loss at 48 weeks
- Have followed GLP-1 research and want to track emerging therapies in the pipeline
- Are curious about glucagon receptor activation and its role in energy expenditure
- Want to compare retatrutide's early data against approved options like semaglutide and tirzepatide
This Research May Not Be Relevant If...
- You want something available now. Retatrutide has reported Phase 3 results but is not yet FDA approved
- You prefer established safety profiles. Long-term data is still being collected
- You need a treatment plan today. Discuss approved options with your healthcare provider first
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)
Bottom Line
What the Data Actually Tells Us
Separating confirmed Phase 2 and Phase 3 findings from what still needs to be established before FDA review.
- Phase 3 TRIUMPH-1 (80 weeks) reported a mean −25.0% body weight change on 12 mg vs −3.9% with placebo (ITT, NEJM, PMID 42814954); Phase 2 reported 24.2% on 12 mg at 48 weeks (PMID 37366315)
- In Phase 2, 100% of participants on the 8mg and 12mg doses lost at least 5% of body weight at 48 weeks (PMID 37366315)
- Gastrointestinal events were the most common adverse events; in Phase 2 they were dose-related, mostly mild to moderate, and partially mitigated by a lower 2 mg starting dose (PMID 37366315)
- In Phase 2, mean weight loss on 12 mg increased from 17.5% at 24 weeks to 24.2% at 48 weeks (PMID 37366315)
- Results from the other Phase 3 TRIUMPH trials are not covered on this page
- Long-term safety beyond the 80-week TRIUMPH-1 treatment period has not yet been established in published data
- No published head-to-head trials against tirzepatide or semaglutide exist. Cross-trial comparisons have real limitations
- FDA approval timeline remains uncertain; retatrutide is still investigational
- Real-world effectiveness may differ from the highly controlled clinical trial setting (adherence, diet, comorbidities)
Mental Clarity, Cognition & Inflammation
Can retatrutide affect focus or inflammatory "stiffness"? No retatrutide trial has tested this. Here is the receptor-level mechanism — and exactly where the evidence stops.
Cognition. In a randomized phase 2b trial in 204 people with mild to moderate Alzheimer's disease, liraglutide showed no significant difference from placebo in cerebral glucose metabolism (the primary endpoint); one secondary executive-function score (ADAS-Exec) performed better with liraglutide at an unadjusted P value, while two other secondary measures (daily activities, dementia rating) showed no significant difference — an exploratory signal, not evidence that liraglutide slows decline (Edison et al., Nat Med 2026, PMID 41326666), and in a randomized trial, exenatide showed better off-medication motor scores than placebo (adjusted between-group difference) in Parkinson's disease (Athauda et al., Lancet 2017, PMID 28781108). Retatrutide also activates GIP and glucagon receptors; whether that adds any cognitive effect has not been tested in a retatrutide trial.
Inflammation. In preclinical models, dual GLP-1 / GIP receptor agonists reduced brain inflammation and protected synaptic numbers and synaptic activity (Hölscher review, Neuropharmacology 2018, PMID 29402504). Systemically, any anti-inflammatory effect could partly reflect fat loss itself, since adipose tissue releases inflammatory signaling molecules such as IL-6 and TNF-α; retatrutide produced large reductions in body weight — a mean 24.2% of total body weight at 48 weeks on the 12 mg dose in the Phase 2 obesity trial (Jastreboff et al., NEJM 2023, PMID 37366315). No retatrutide trial cited here measured inflammatory markers.
Continue Reading
Related Resources
Calculators, vendor guides, and dosing information for weight loss peptides.
More Research
Related Research Guides
Essential Supplies
Everything you need for peptide preparation and administration
Affiliate links support HighPeptides at no extra cost.
What to Expect: A Patient Timeline
Based on the retatrutide Phase 2 trial (NEJM 2023, NCT04881760, n=338, PMID 37366315) at the highest dose (12 mg/week), plus the Phase 3 TRIUMPH-1 result where noted. Lower doses produced smaller effects, with the dose response flattening between 8 mg and 12 mg. Individual results vary significantly.
Triple Receptor Activation & Dose Escalation
Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors — a triple mechanism that distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GIP + GLP-1). GLP-1 activity is thought to suppress appetite; the GIP and glucagon components are thought to add metabolic effects, which has not been measured directly in these trials. In Phase 2 the 12 mg group started at 2 mg; GI events were the most common adverse events, were dose-related, and were partially mitigated by the lower starting dose (PMID 37366315).
Early Weight Loss
The glucagon receptor component of retatrutide is thought to raise energy expenditure, a proposed mechanism rather than a measured trial result. The trial abstracts do not report month-1 weight change or food intake.
Week-24 Weight Loss
By week 24, the 12 mg group in the Phase 2 trial showed a mean 17.5% body weight loss, versus 1.6% with placebo (PMID 37366315). Week 24 was the trial's primary endpoint.
Continued Weight Loss to 48 and 80 Weeks
The Phase 2 trial showed 24.2% average body weight loss at 48 weeks in the highest-dose group (12 mg), versus 2.1% with placebo (PMID 37366315). In the separate, larger Phase 3 TRIUMPH-1 trial, the 12 mg group's mean body weight change at 80 weeks was −25.0% versus −3.9% with placebo under intention-to-treat (NEJM, PMID 42814954).
Sleep Apnea Data — and Nausea Around Bedtime
The weight loss driven by GLP-1/GIP/glucagon tri-agonists like retatrutide may also benefit obesity-related sleep apnea. In TRIUMPH-1, participants with obstructive sleep apnea had apnea-hypopnea index (AHI) changes of up to −34.3 events/hour (9 mg, ITT) vs −9.6 with placebo (NEJM, PMID 42814954).
GI effects such as nausea were the most common adverse events in the trials and could plausibly interfere with sleep; how dose timing affects sleep has not been studied in retatrutide trials.
→ Sleep Optimization for GLP-1 UsersRetatrutide (Research Peptide)
The triple-agonist (GLP-1/GIP/glucagon) with reported Phase 3 TRIUMPH-1 results. Research peptides are not FDA-approved for human use. Review each product’s certificate of analysis before buying.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Retatrutide is an investigational drug not yet approved by the FDA for any indication. Always consult with a qualified healthcare provider before starting any medication or treatment protocol. Data sourced from published peer-reviewed research (NEJM 2023, NCT04881760; NEJM 2026, NCT05929066) unless otherwise cited.
Related Resources
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.